The story of Viagra, formerly marketed by copyright, presents a intricate case study for backers considering the pharmaceutical sector. Although its initial success and generation of vast in earnings , the patent lapse has opened the floodgates for competing medications, greatly reducing profit opportunities. This change raises questions about the